At the IATI Biomed conference held in Tel Aviv in May, Medtronic executives hint at an increasing focus on diagnostics, personalized medicine, and patient outcomes.
Medtronic PLChas been one of the most acquisitive companies in recent years, clocking seven deals in 2014. And in spite of splashing a record $43 billion on Medtronic Minimally Invasive Therapies, the biggest pure-play medtech company doesn’t look like it’s planning to stop shopping any time soon. (See[A#01150202003].)
So what areas is Medtronic looking at? Diagnostics and personalized medicine could be sectors of interest, hinted Geoffrey Martha, senior...
Waters Corp. will acquire Becton Dickinson’s Biosciences and Diagnostics business for $17.5bn, doubling its TAM to $40B. Analysts praise the flow cytometry addition but see weaker growth in diagnostics.
An interactive look at medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.
Thena Capital, the first UK-based early-stage specialist medtech firm, has made its first investment since closing its £50m fund. Medtech Insight spoke with general partner Pamela Walker Geddes to gain insight into Thena Capital’s investment strategy.
The Milner Institute, the on-campus hub for start-up acceleration at Cambridge University, hosted its annual Pitch Day on July 1. Start-ups Panakeia, PathwayBio and Sentinal4D presented diagnostic technologies.
CEO Alexandre Chau told Medtech Insight that the Middle East and Africa presented the ideal mix of market potential, physician training opportunities, and regulatory readiness when the company was considering expansion markets beyond Europe and the US.
A recent approval from the US FDA allowing Boston Scientific to broaden its labeling for its pulse field ablation system means more patients with one type of AFib will have access to a promising new treatment.
Thena Capital, the first UK-based early-stage specialist medtech firm, has made its first investment since closing its £50m fund. Medtech Insight spoke with general partner Pamela Walker Geddes to gain insight into Thena Capital’s investment strategy.
